Cardior Exploring MicroRNAs As Heart Failure Target
Executive Summary
Emerging Company Profile: The German company Cardior has been set up to evaluate inhibitors of a microRNA in the treatment of heart failure, a condition that is poorly treated by current therapies.
You may also be interested in...
Venture Funding Deals: $65m For Iterum's Antibiotic; Genoa's IPF Drug Nets $62m
Iterum Therapeutics and Genoa Pharmaceuticals topped the list of biopharmaceutical start-up firms closing new venture capital rounds in May with $65m and $62m, respectively, to advance drug candidates for bacterial infections and idiopathic pulmonary fibrosis.
With Serial Entrepreneur At Its Helm, Arrakis Raises $38m To Target RNA With Small Molecules
Serial entrepreneur Michael Gilman has taken the helm of another start-up; after selling Padlock to Bristol-Myers and Stromedix to Biogen, his new company Arrakis has raised a $38m Series A round with big biopharma backing.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.